...
机译:关于新型疗法时代的宏观焦瘤(MFMM)患者发病率,临床特征和结果的现实数据:Greco-以色列合作骨髓瘤工作组的研究
Theagenio Canc Hosp Dept Hematol Thessaloniki Greece;
Univ Athens Sch Med Dept Clin Therapeut Athens Greece;
Hebrew Univ Jerusalem Med Ctr Hadassah Hematol Dept Shoeva Israel;
Tel Aviv Univ Aviv Sourasky Ichilov Med Ctr Dept Hematol Tel Aviv Israel;
Tel Aviv Sourasky Med Ctr Inst Hematol Tel Aviv Israel;
Agios Savvas Hosp Hematol Dept Athens Greece;
George Papanicolaou Hosp Dept Hematol Thessaloniki Greece;
Rambam Hlth Care Campus Dept Hematol &
Bone Marrow Transplantat Haifa Israel;
Evangelismos Med Ctr Dept Hematol Lymphoma &
BMT Unit Athens Greece;
Univ Athens Laikon Gen Hosp Dept Propaedeut Internal Med 1 Athens Greece;
Nicosia Gen Hosp Dept Hematol Nicosia Cyprus;
Galilee Med Ctr Nahariyya Israel;
Soroka Med Ctr Beer Sheva Israel;
Asaf Harofe Med Ctr Zerifin Israel;
George Papanicolaou Hosp Dept Hematol Thessaloniki Greece;
Metaxa Hosp Hematol Lab Piraeus Greece;
Gen Hosp Patras St Andrrew Dept Haematol Patras Greece;
Shaare Zedek Med Ctr Dept Haematol Jerusalem Israel;
Rabin Med Ctr Davidoff Canc Ctr Inst Hematol Petah Tiqwa Israel;
Emek Med Ctr Dept Hematol Afula Israel;
Democritus Univ Thrace Sch Med Dept Hematol Alexandroupolis Greece;
Univ Athens Sch Med Dept Clin Therapeut Athens Greece;
Hadassah Hebrew Univ Med Ctr Jerusalem Israel;
Theagen Canc Hosp Dept Hematol Thessaloniki Greece;
Univ Athens Sch Med Dept Clin Therapeut Athens Greece;
St Savvas Oncol Hopsital Dept Hematol Athens Greece;
Univ Athens Laikon Gen Hosp Dept Propaedeut Internal Med 1 Athens Greece;
Theagen Canc Hosp Dept Hematol Thessaloniki Greece;
Theagen Canc Hosp Dept Hematol Thessaloniki Greece;
Theagen Canc Hosp Dept Hematol Thessaloniki Greece;
G Papanikolaou Hosp Hematol Dept Thessaloniki Greece;
Univ Athens Sch Med Dept Clin Therapeut Athens Greece;
Univ Athens Alexandra Hosp Sch Med Dept Clin Therapeut Athens Greece;
机译:关于新型疗法时代的宏观焦瘤(MFMM)患者发病率,临床特征和结果的现实数据:Greco-以色列合作骨髓瘤工作组的研究
机译:ERA-EDTA注册研究对因多发性骨髓瘤或轻链沉积病导致的终末期肾脏疾病开始肾脏替代治疗的患者的发生率和结果:
机译:对于多发性骨髓瘤或轻链沉积疾病导致的终末期肾脏疾病,开始肾脏替代治疗的患者的发生率和预后:一项ERA-EDTA注册研究。
机译:评估来自医院信息系统的自动导出临床资料中多发性骨髓瘤的临床研究
机译:评估多发性骨髓瘤患者糖尿病患者的患病率和结果
机译:骨髓微环境有助于新诊断的多发性骨髓瘤的患者结果:在总疗法临床试验中的患者队列研究
机译:奥地利多发性骨髓瘤的第三线治疗的实际应用:奥地利骨髓瘤登记(amR)分析使用下一代骨髓瘤治疗前的治疗前景和临床结果。